Moreover, our finding that high expression of both LSD1 and G9a is associated with poor outcome in patients with ESCC suggests that inhibiting both LSD1 and G9a may represent a promising strategy for treating these patients. Here, EHMT2 is linked to esophageal squamous cell carcinoma.